trial

Oxytocin Treatment of Schizophrenia

NCTId NCT01028677
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 17 (actual)
Sponsored by University of North Carolina, Chapel Hill
Primary completion 2011-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
17 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2009-11
Primary completion
2011-03
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
intranasal spray with oxytocinnasal spray without oxytocin

Sponsors

University of North Carolina, Chapel HillLead Sponsor

Investigators

1
Cort A Pedersen, M.D.Principal Investigator

Sites

1 total
Chapel Hill, United States

Facts & assertions

4 sourced
Enrollment
17
Phase
NA
Primary Completion Date
2011-03
Status
COMPLETED
relationships
The graph out of here
drug
intranasal spray with oxytocin
drug
nasal spray without oxytocin
drug
lead_sponsor
University of North Carolina, Chapel Hill
company
indication
Paranoia
indication
Schizoaffective Disorder
indication
Social Skills
indication
investigator
Cort A Pedersen, M.D.
person